Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Major Medical Systems Used for 10.3 Years
July 30, 2007
- Alfresa to Reduce SGA Expanses Ratio to Below 6% by FY2009
July 30, 2007
- MEDICAL DEVICE NEWS IN BRIEF
July 30, 2007
- BUSINESS NEWS IN BRIEF
July 30, 2007
- Benefits for OTC-Like Ethical Drugs to Be Reviewed in 4 to 5 Years
July 30, 2007
- 11 Generic Products (6 APIs) to Be Listed in November
July 30, 2007
- SELF-MEDICATION NEWS IN BRIEF
July 30, 2007
- NPhA to Further Promote Use of Generics
July 30, 2007
- OPINION／Once in a Lifetime
July 30, 2007
- MD Studies to Be Permitted at a Total Dose of 500 μg: Dr Ohno
July 30, 2007
- TOPICS／Mebix Starts Home Blood Pressure Management Service
July 30, 2007
- RIKEN, Harvard Univ. Hospital Decipher Protein Structure of LTC4 Synthase
July 30, 2007
- Nutrition Management Improves QOL, Reduces Costs: Prof. Ohyanagi
July 30, 2007
- NanoCarrier Obtains Patent on Macromolecular Micelles
July 30, 2007
- Adiponectin Stimulates Appetite in the Brain: Prof. Kadowaki
July 30, 2007
- R&D NEWS IN BRIEF(1)
July 30, 2007
- Schizophrenia Patients Must Be Treated with Fewer Drugs, at Lower Doses: Seminar
July 30, 2007
- R&D NEWS IN BRIEF(2)
July 30, 2007
- R&D NEWS IN BRIEF
July 23, 2007
- Promote Multinational Clinical Trials to Eliminate Drug Lag: Study Group
July 23, 2007
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…